Drugs / EP-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01706536 | Oct 2012 → Apr 2013 | chronic obstructive pulmonary disease | Sunovion Respiratory Development Inc. | Completed | Met primary |
| Phase 2 | NCT01426009 | Aug → Dec 2011 | chronic obstructive pulmonary disease | Sunovion Respiratory Development Inc. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EP-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01706536 ↗ |
| Route | Inhaled | “EP-101 via nebulizer (eFlow®) 25 ug” NCT01426009 ↗ |